The United Kingdom and the United States have forged a important commercial pact that will keep zero import taxes on British medicine exports going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost spending on medicines through the NHS. This commitment ensures that import taxes on these vital exports will remain at zero for a timeframe of three years.
This development follows recent warnings to hike duties on patented pharmaceutical imports, with figures floated reaching 100%.
"This agreement between the Britain bolsters the international landscape for innovative medicines and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement declared.
Trade Importance
Drugs constitute one of the Britain's most significant export categories to the America, which is easily the largest buyer for leading companies like GSK and AstraZeneca.
Export figures show that in the year prior to last September, the UK sold drugs valued at billions to the US. This figure made up nearly one-fifth of British export trade in that period.
"This agreement protects work, increases capital expenditure and paves the way for the UK to emerge as a global hub for medical research," a minister remarked.
Detailed UK Commitments
The agreement involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to double total health service expenditure on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be capped at 15%. Previously, refunds exceeded 20%.
Recent Tensions
The pact follows a protracted tension between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were exacerbated by claims that US customers were charged significantly more for the equivalent treatments than people in the UK and Europe.
Recently, several large drug company projects in the UK have been delayed or cancelled, while substantial expansions have been announced toward American operations.
One official publicly accepted that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the past decade.
